Wednesday, August 4, 2021

Red Meat | Prevention | Antibiotics, Cancer Information Highlights, 08/04/2021

National Cancer Institute

Having trouble viewing this email? View it as a Web page.

Bookmark and Share

Cancer Information Highlights
From the National Cancer Institute
Updating you about cancer causes, prevention, screening, treatment, coping, and more
 
New from NCI
DNA Damage Links Colorectal Cancer and Diet High in Red Meat
pile of hamburger   Researchers have found a pattern of DNA damage in colorectal tumors that may explain how a diet high in red and processed meat can help cause colorectal cancer.
Advancing Cancer Prevention
Dr. Philip Castle   The director of NCI's Division of Cancer Prevention, Dr. Philip Castle, discusses the division's priority areas and his vision for making more rapid progress in cancer prevention, including the use of precision prevention and immunoprevention.
Can an Antibiotic Treat Cancer?

Researchers have found that an antibiotic discovered in the 1950s, novobiocin, may kill cancer cells that become resistant to PARP inhibitors. Learn more about this research and the clinical trials that are planned.
How Cancer Research Saved Emily's Life
Emily Whitehead and her parents   In 2012, Emily Whitehead was the first child in the world to receive CAR T-cell therapy. Read about her story and the treatment that saved her life.
Approval of Rylaze Will Address Drug Shortage for Childhood ALL

The Food and Drug Administration (FDA) has approved a new form of asparaginase called Rylaze. The drug was developed to help ease shortages of Erwinia asparaginase, a key part of treatment for children and adults with acute lymphoblastic leukemia (ALL).

FDA Approvals
Amivantamab-vmjw

We've added a new drug summary for amivantamab-vmjw (Rybrevant). FDA recently approved this drug to treat adults with non-small cell lung cancer that has spread, has an abnormal EGFR gene, and has worsened during or after platinum chemotherapy.
Pembrolizumab

We've updated our pembrolizumab (Keytruda) drug summary. FDA recently approved pembrolizumab to treat patients with high-risk, early-stage triple-negative breast cancer. FDA also converted pembrolizumab from accelerated approval to full approval to treat people with triple-negative breast cancer that has the PD-L1 protein and has come back and cannot be removed by surgery or has spread.
 
Also of Interest
Hot Flashes and Night Sweats

Hot flashes and night sweats can be caused by cancer or a side effect of treatment. They can occur in both women and men. Learn more about hot flashes and night sweats and ways to treat them.
Coronavirus Vaccines and People with Cancer

Many people being treated for cancer are asking whether they should get a COVID-19 vaccine. On this page, an expert answers questions and responds to concerns about the vaccine.
Contact Us for Help

Information specialists at NCI's Cancer Information Service (CIS), NCI's contact center, are available to help answer your cancer-related questions in English and Spanish. Reach us by phone, chat, or email.

 

This email was sent to myhcistech.healthnews360@blogger.com using GovDelivery Communications Cloud on behalf of: National Cancer Institute · BG 9609 MSC 9760 · 9609 Medical Center Drive · Bethesda, MD 20892 GovDelivery logo

No comments:

Post a Comment